Victory Capital Management
TBPH icon

Victory Capital Management’s Theravance Biopharma TBPH Stock Holding History

Victory Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241K Buy
+14,170
New +$235K ﹤0.01% 2220
2023
Q1 		– Sell
-158,470
Closed -$1.78M – 2689
2022
Q4 		$1.78M Buy
158,470
+48,120
+44% +$506K ﹤0.01% 1484
2022
Q3 		$1.12M Buy
110,350
+46,700
+73% +$438K ﹤0.01% 1678
2022
Q2 		$577K Buy
+63,650
New +$586K ﹤0.01% 1984

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Victory Capital Management's TBPH Position: Q2 2026 in Review

Victory Capital Management opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 14,170 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #2220 among its holdings. This is a return to the name: Victory Capital Management previously reported a position in TBPH as recently as Q4 2022.

Victory Capital Management first reported a position in TBPH in Q2 2022 and has held it in 4 quarters since. The position peaked at $1.78M in Q4 2022. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Victory Capital Management held 14,170 shares of Theravance Biopharma worth $241K as of Q2 2026.
  • Theravance Biopharma was a new Victory Capital Management position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2220 holding.
  • Victory Capital Management first reported a position in Theravance Biopharma in Q2 2022 and has held it in 4 quarters since.
  • Victory Capital Management's Theravance Biopharma position peaked at $1.78M in Q4 2022.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.